Xenon Pharmaceuticals XENE Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Axsome TherapeuticsAXSM

$23.01M-5.5%

Stoke Therapeutics, Inc.STOK

$3.42M-42.5%

Praxis Precision Medicines, Inc.PRAX

$1.4M—

Rapport Therapeutics, Inc.RAPP

$11.48M+678%

LBR

LB Pharmaceuticals IncLBRX

$3.47M—

XencorXNCR

$65.21M-4.0%

FAQ

What is Xenon Pharmaceuticals's operating lease liabilities (total)?

Xenon Pharmaceuticals (XENE) reported operating lease liabilities (total) of $6.42M in Q2 2026.

How has Xenon Pharmaceuticals's operating lease liabilities (total) changed year-over-year?

Xenon Pharmaceuticals's operating lease liabilities (total) decreased by 26.4% year-over-year, from $8.72M to $6.42M.

What is the long-term trend for Xenon Pharmaceuticals's operating lease liabilities (total)?

Over 5 years (2020 to 2025), Xenon Pharmaceuticals's operating lease liabilities (total) has grown at a 19.1% compound annual growth rate (CAGR), from $3.32M to $7.94M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.